Posted by Michael Wonder on 09 Dec 2021
InnoCare announces inclusion of orelabrutinib in China National Reimbursement Drug List
2 December 2021 - InnoCare Pharma announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List by the China National Healthcare Security Administration.
Orelabrutinib is an oral, once daily BTK inhibitor with national Category 1 designation.
It is included in the National Reimbursement Drug List as the treatment of patients with relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma and the treatment of patients with relapsed/refractory mantle cell lymphoma.
